Does CyberKnife improve dose distribution versus IMRT and VMAT on a linear accelerator in low-risk prostate cancer? Cover

.blurhash-client-img { display: none !important; }

Does CyberKnife improve dose distribution versus IMRT and VMAT on a linear accelerator in low-risk prostate cancer?

Radiology and Oncology

Volume 56 (2022): Issue 2 (June 2022)

By: Dorota Maria Borowicz, Agnieszka Skrobała, Marta Kruszyna-Mochalska and Julian Malicki

Open Access

|Mar 2022

Authors

Dorota Maria Borowicz

dorota.borowicz@wco.pl

Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland

Agnieszka Skrobała

Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland

Electroradiology Department, University of Medical Sciences, Poznan, Poland

Marta Kruszyna-Mochalska

Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland

Electroradiology Department, University of Medical Sciences, Poznan, Poland

Julian Malicki

Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland

Electroradiology Department, University of Medical Sciences, Poznan, Poland

DOI: https://doi.org/10.2478/raon-2022-0010 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Journal RSS Feed

Language: English

Page range: 259 - 266

Submitted on: Oct 21, 2021

Accepted on: Jan 31, 2022

Published on: Mar 28, 2022

Published by: Association of Radiology and Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

prostate carcinoma,

stereotactic radiotherapy,

intensity-modulated radiotherapy,

Related subjects:

Clinical medicine,

Internal medicine,

Haematology, oncology,

© 2022 Dorota Maria Borowicz, Agnieszka Skrobała, Marta Kruszyna-Mochalska, Julian Malicki, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 56 (2022): Issue 2 (June 2022)